Image Quantification in Neuro-Oncology Clinical Trials
Perceptive Medical Imaging Delivers More Precise Brain Tumor Assessments
Assessing brain tumors in a standardized manner to characterize treatment response is complex. Although RANO criteria are commonly utilized for neuro-oncology clinical trials, there is a growing need for objective and quantitative markers to assess tumor size and characteristics. However, volumetric tumor assessments, which currently need to be conducted manually by neuroradiologists, are time-consuming and challenging.
To overcome this, Perceptive Medical Imaging partners with Neosoma, an innovative medical technology company whose AI-based neuro-oncology software device is shown to achieve high accuracy in tumor volume measurement and consistent, faster, and more precise assessments of tumor change.
Neosoma’s solution provides automated 3D intratumoral segmentation and longitudinal volumetric measurements by ingesting standard MRI sequences (pre- and post-contrast T1w, T2w, and FLAIR sequences) and by outputting the volumes of enhancing, T2/FLAIR, and necrosis/surgical cavity parts of the high-grade gliomas.
The solution can be deployed within Perceptive’s infrastructure without presenting risks to data custody/security, to assist criteria-based assessments for supporting active clinical trial endpoints and for retrospective analysis.
The combination of Perceptive’s experience supporting nearly 100 neuro-oncology clinical trials and Neosoma’s AI-based marker approach gives sponsors a comprehensive assessment of their compounds targeting brain cancer.
For more information on Perceptive’s neuro-oncology trial imaging experience:
